Roxana I. Sufan
Publications by Year
Research Areas
Colorectal Cancer Treatments and Studies, Cancer, Hypoxia, and Metabolism, HER2/EGFR in Cancer Research, Lung Cancer Treatments and Mutations, Gastric Cancer Management and Outcomes
Most-Cited Works
- → VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail(2006)240 cited
- → Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial(2020)91 cited
- → Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia(2011)80 cited
- → The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma(2004)72 cited
- → Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer(2018)56 cited
- → Role of the NEDD8 Modification of Cul2 in the Sequential Activation of ECV Complex(2006)43 cited
- → Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.(2019)33 cited
- → Oxygen‐independent degradation of HIF‐α via bioengineered VHL tumour suppressor complex(2009)23 cited
- → DCNL1 Functions as a Substrate Sensor and Activator of Cullin 2-RING Ligase(2013)21 cited
- → IMpower150: Exploratory analysis of brain metastases development.(2020)16 cited